Seoul:The pharmaceutical industry is being called upon to revise its business models and partnerships to make medicines more affordable and accessible, especially in regions with the greatest need. Efforts over the past two decades have focused on convincing pharmaceutical leaders of the importance of equitable access to medicines, a sentiment that is widely shared but lacks the incentives necessary for implementation at scale.
According to World Economic Forum, the pharmaceutical industry's role in global health is critical, as it drives innovation and determines the registration, pricing, and accessibility of medicines. However, with scientific advancements outpacing delivery systems, there is a pressing need for change. The latest edition of the Access to Medicine Index highlights that while companies increasingly view access as a strategic priority, progress is inconsistent, with geopolitical and economic factors posing additional challenges.
The report notes that many companies are now incorporating access plans into their operations, with 69% of late-stage pipeline candidates covered, a significant increase from 2018. Despite this, disparities remain, particularly in non-communicable diseases like cancer, diabetes, and obesity, where access initiatives tend to favor wealthier regions.
Emerging markets present a significant opportunity for growth, yet access plans often fall short in these areas. The development of new business models, such as offering lower-priced medicine portfolios, is essential for making equitable access a viable commercial strategy. The pharmaceutical industry must adopt diverse approaches to close the access gap and meet the growing demand in low- and middle-income countries.
The World Economic Forum emphasizes the importance of integrating social and environmental benefits into corporate strategies. Shareholders and companies alike are increasingly recognizing the need to prioritize access in business operations to ensure that scientific innovations reach those who need them most.
